RAC Race Oncology Ltd
- 1.790
- -0.075-4.02%
Race Oncology Ltd News
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%
Race Oncology (ASX:RAC) validated the efficacy of its bisantrene therapy medication to slow the progress of multiple myeloma, a form of blood cancer, in cell culture and mice models, according to a Th
Race Oncology Receives FDA Orphan Drug Designation Extension for Bisantrene RC220 | ASX:RAC, OTC:RAONF
Race Oncology Ltd Issues New Stock Options
Race Oncology's Breakthrough in Cancer Cell Treatment | ASX:RAC, OTC:RAONF
Why Credit Corp, GUD, Race Oncology, and Spartan Resources Shares Are Rising
The S&P/ASX 200 Index (ASX: XJO) is having a tough session on Tuesday. In afternoon trade, the benchmark index is down 0.4% to 7,719.1 points.
2 ASX Healthcare Shares Rocking Higher on Big News
ASX healthcare shares are one of only two market sectors trading in the green at the time of writing.
Race Oncology Reports "Enhancement" of Cancer Cell-killing Capabilities
Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed Phase I/II leukaemia trial.
Race Oncology Ltd Announces New Options Issue
Will Race Oncology (ASX:RAC) Spend Its Cash Wisely?
Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%
Race Oncology (ASX:RAC) received a certificate of analysis from Ardena for the first current Good Manufacturing Practice batch of its RC220 bisantrene formulation, attesting to the drug product's comp
Race Oncology Appoints Brendan Brown as Chief Financial Officer
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has appointed experienced corporate and financial executive Brendan Brown as its chief financial officer (CFO), effective from Monday, April 1, 2024.
Race Oncology Adds International Cardiometabolic Expert to Scientific Advisory Board
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has appointed international cardiometabolic expert Associate Professor Erin Howden of the Baker Heart and Diabetes Institute in Melbourne, Australia, to the company’s Scientific Advisory Board (SAB).
Race Oncology Says Study Shows Lead Asset's Efficacy in Blood Cancer Treatment
Race Oncology (ASX:RAC) said its lead asset, bisantrene, demonstrated "potent activity" in the treatment of acute myeloid leukemia (AML) in diverse cell and animal models. Research conducted by the co
Race Oncology's New Study Highlights Bisantrene's Efficacy in Treatment for Acute Myeloid Leukemia
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has struck another blow in the fight against acute myeloid leukemia (AML) with the release of a study investigating the potent anticancer activity of the company’s lead asset, bisantrene.
Race Oncology Widens Loss in Fiscal H1
Race Oncology (ASX:RAC) reported Wednesday that its loss for the half-year ended Dec. 31, 2023, was AU$5.7 million, widening from AU$4.4 million in the year-ago period. Diluted loss per share was AU$0
Race Oncology Receives $4 Million R&D Tax Refund
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has received a $4 million R&D tax incentive from the Australian Taxation Office (ATO) for FY2023.
Race Oncology Names CEO; Shares Jump 5%
Race Oncology (ASX:RAC) appointed Daniel Tillett as its chief executive officer with immediate effect, the biotechnology firm said on Wednesday. Tillett will work alongside executive director Pete Smi
Race Oncology Initiates Toxicology, Safety Pharmacology Studies of Chemotherapy Drug
Race Oncology (ASX:RAC) tapped Attentive Science in the US and Agilex Biolabs in Australia to conduct toxicology and safety pharmacology studies of RC220. The studies are required to support human cli
Race Oncology (ASX: RAC) Announces Key Leadership Changes Following CEO Resignation
Race Oncology (ASX:RAC) Receives $1.66m R&D Tax Refund
Analysis
Price Target
No Data
